

Appl. No. 09/676,835


Supplemental Amendment dated October 31, 2003

This listing of claims will replace all prior versions and listings of claims in this application.

### Listing of Claims

Claims 1-8 (cancelled)

Claim 9 (Currently Amended) A method of treating a subject suffering from a neoplastic condition or toxicity associated with an alteration in sphingolipid metabolism comprising administering to the subject an effective amount of a fumonisin analog of the formula:



wherein the spacer group is selected from the group consisting of ~~alkyl~~ (straight chain or branched, C<sub>1</sub> - C<sub>20</sub>) alkyl, ~~hydroxyalkyl~~ (straight chain or branched, C<sub>1</sub> - C<sub>20</sub>) hydroxyalkyl and ~~dihydroxyalkyl~~ (straight chain or branched, C<sub>1</sub> - C<sub>20</sub>) dihydroxyalkyl; Z is selected from the group consisting of H, O, NH, NQ, NQC(O), NHC(O), CO<sub>2</sub>, C(O)NH, and C(O)NQ, wherein Q is ~~an alkyl~~ (straight chain or branched, C<sub>1</sub> - C<sub>6</sub>) alkyl; W is selected from the group consisting of no substituent, H, ~~alkyl~~ (straight chain or branched, C<sub>1</sub> - C<sub>6</sub>) alkyl, ~~aryl~~ (phenyl or substituted phenyl) aryl, C(O)(CH<sub>2</sub>)<sub>n</sub>CO<sub>2</sub>H [wherein n = 1-6], C(O)(CH<sub>2</sub>)<sub>n</sub>CW'<sub>2</sub>CO<sub>2</sub>H, where W' is selected independently from H, ~~alkyl~~ (straight chain or branched, C<sub>1</sub> - C<sub>6</sub>) alkyl, ~~aryl~~ (phenyl or substituted phenyl) aryl, and (CH<sub>2</sub>)<sub>n</sub>CO<sub>2</sub>H, wherein n = 1-6; X is selected from the group consisting of H, methyl, CH<sub>2</sub>OH [and esters thereof], CH<sub>2</sub>NQ'<sub>2</sub> (where Q' is selected independently from H, ~~alkyl~~ (straight chain or branched, C<sub>1</sub> - C<sub>20</sub>) alkyl, and acyl, wherein acyl is defined as [C(O)Q" where Q" is ~~an alkyl~~, straight chain or branched, C<sub>1</sub> - C<sub>20</sub>) alkyl; and V and Y are independently selected from the group consisting of H or OH [and esters thereof] but not fumonisin B1, fumonisin B2, fumonisin B3, fumonisin B4 or AAL toxin.

Appl. No. 09/676,835

Supplemental Amendment dated October 31, 2003

Claim 10 (cancelled)

Claim 11 (currently amended)      The method of Claim 9, wherein the subject has Neimann-Picks syndrome or Tay-Sachs disease ~~is treated~~.

Claim 12 (currently amended)      The method of Claim 9, wherein the ~~fumonisin or~~ fumonisin analog is administered in an amount between 5 and 500 mg.

Claim 13 (currently amended)      The method of Claim 9, wherein the ~~fumonisin or~~ fumonisin analog is administered in an amount between 25 and 75 mg.

Claim 14 (previously presented)      The method of Claim 9, wherein X is CH<sub>2</sub>OH or an ester thereof.

Claim 15 (previously presented)      The method of Claim 9, wherein the fumonisin analog has a 2-amino-3,5-diol head group.

Claim 16-46 (cancelled)

Claim 47 (previously presented)      The method of Claim 9, wherein the neoplastic condition is esophageal cancer.

Claim 48 (previously presented)      The method of Claim 9, wherein the subject is a human.

Claim 49 (previously presented)      The method of Claim 9, wherein V is hydroxyl.

Claim 50 (previously presented)      The method of Claim 9, wherein V is hydrogen and Y is hydrogen.

Appl. No. 09/676,835

Supplemental Amendment dated October 31, 2003

Claim 51 (previously presented)      The method of Claim 9, wherein V is hydroxyl and Y is hydrogen.

Claim 52 (previously presented)      The method of Claims 50 or 51, wherein X is methyl.

Claim 53 (previously presented)      The method of Claim 9, wherein the spacer group is alkyl, Z is hydrogen and W is no substituent.

Claim 54 (previously presented)      The method of Claim 9, wherein Y is hydrogen, V is hydroxyl, Z is hydrogen and the spacer group is C<sub>1</sub>- C<sub>20</sub>.

Claim 55 (previously presented)      The method of claim 9, wherein Z is hydrogen.

Claim 56 (previously presented)      The method of claim 9, wherein the spacer group is alkyl (straight chain or branched, C<sub>1</sub> - C<sub>20</sub>).

Claim 57 (previously presented)      The method of claim 9, wherein W is no substituent.

Appl. No. 09/676,835

Supplemental Amendment dated October 31, 2003

It is believed that this Supplemental Amendment places the application in condition for allowance. If there are any issues that can be resolved with an Examiner's Amendment or a telephone conference, a telephone call to the undersigned attorney at 404-572-3541 is respectfully requested.

Respectfully submitted,



Sherry M. Knowles, Esq.

Reg. No. 33,052

King & Spalding  
45<sup>th</sup> Floor  
191 Peachtree Street, N.E.  
Atlanta, Georgia 30303  
404-572-3541  
Fax: 4.4-572-5145

K&S Docket: 18085.105300